Gastroesophageal-junction Cancer research hub
3 indexed studies · 2 currently recruiting
- recruitingPHASE3
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
This study looks at a new medicine called HLX22, combined with standard treatments, for people newly diagnosed with a certain type of stomach and food pipe cancer. It aims to see how well it works and if it's safe compared to current treatments.
United States · Argentina · Australia - active not recruitingPHASE1
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
This study is testing a new drug, ELVN-002, with existing treatments like trastuzumab and chemotherapy. It's for adults with certain advanced HER2-positive cancers, including breast, stomach, and bowel cancer. The main goal is to find a safe dose and see how well it works.
United States · Belgium · France - recruitingPHASE3
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
This study looks at new drug combinations for stomach (gastric) or food pipe (GEJ) cancer that has a specific marker called HER2. It compares different treatment mixes to see which works best and is safest for advanced cancer.
United States · Argentina · Australia